Welcome to the 2008 Universities Innovation Showcase
Date: Thursday 22 May 2008
|
|
Universities Innovation Showcase BrochureThis collaborative activity by research-focused Victorian universities aims to demonstrate the value created by university and industry engagement - it demonstrates how universities can deliver business solutions for industry.
Aimed at decision makers in business, industry and government, the 2008 event will demonstrate how:
- Industry and universities can partner in ARC Industry Linkage grants
- Businesses can access student industry placements and employment
- Industry and businesses can effectively engage with universities
Participating universities:
- Australian Catholic University
- Ballarat
- Deakin
- La Trobe
- Melbourne
- Monash
- RMIT
- Swinburne
- Victoria
Now in its third year, the event builds connections between business and universities. The universities showcase their knowledge, unique research capabilities, and their readiness to engage with industry.
Register online today or email Gael Andrews: gael.andrews@ozemail.com.au for more information.
Phillips Ormonde & Fitzpatrick client, Acrux, is an innovative Australian drug delivery company, developing and commercialising a range of transdermal products for global markets. The technology was spun out of Monash University in 1999 and Acrux listed on the Australian stock exchange in 2004. Phillips Ormonde & Fitzpatrick has assisted the company file and prosecute more than 150 patents and registered designs in all major territories globally.
In simple terms, Acrux’s technology delivers drugs through the skin using a metered dose spray applicator that delivers a precise dose to the skin surface. The spray dries very quickly and allows the drug to be delivered continuously over a long period of time, and therefore only needs to be applied once a day. The delivery mechanism offers a number of advantages to patients, including easy, discreet and convenient administration, fast drying and quickly absorbed formulation, non-irritating and non-invasive to the skin and invisible after application, thereby avoiding the need for patches, pills or injections. Last month, Acrux announced that its first product, EvaMist™, had been launched in the US. Evamist™ is the first and only estradiol transdermal spray, and is indicated for the treatment of moderate-to-severe vasomotor symptoms due to menopause.